Ridogrel is a dual-action therapeutic agent classified as a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, primarily utilized for the prevention… Read more
Ridogrel is a dual-action therapeutic agent classified as a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, primarily utilized for the prevention of systemic thromboembolism and as an adjunctive agent in acute myocardial infarction therapy. This category provides comprehensive reference standards for this potent antiplatelet agent, including high-quality Ridogrel API, along with its related impurities, metabolites, and stable isotope-labelled compounds. Pharmaceutical laboratories rely on these specialized materials for precise analytical testing, impurity profiling, and the rigorous method validation required for quality control. By incorporating these accurate reference standards into laboratory workflows, researchers ensure the reliability and consistency of their data when studying the pharmacological profile of this compound. These materials are essential for supporting the development and monitoring of high-standard pharmaceutical products in cardiovascular research and related drug analysis.